trending Market Intelligence /marketintelligence/en/news-insights/trending/MILatXrxknowI6JluwJQCg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

CVS beats Q2 earnings estimates, raises FY'19 guidance

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

CVS beats Q2 earnings estimates, raises FY'19 guidance

CVS Health Corp.'s second-quarter adjusted EPS and net income exceeded analyst expectations Aug. 7 as the company raised its profit expectations for full year 2019.

Adjusted EPS for the three months to June 30 of $1.89 surpassed the S&P Global Market Intelligence estimate for normalized EPS of $1.69. Adjusted net income rose 43% to $2.46 billion from $1.72 billion, beating the Market Intelligence estimate for net income excluding exceptions of $2.21 billion.

The Woonsocket, R.I.-based pharmacy chain raised its guidance for 2019 adjusted EPS to a range between $6.89 and $7.00, up from a range between $6.75 and $6.90. It also narrowed its GAAP diluted EPS expectations to a range between $4.93 and $5.04 from between $4.90 and $5.05.

CVS also now expects adjusted operating income of between $15.2 billion and $15.4 billion, up from between $15 billion and $15.2 billion. The company confirmed its outlook for consolidated GAAP operating income, saying it still expects the metric in a range between $11.8 billion and $12 billion.

For the third quarter, CVS expects adjusted EPS of between $1.75 and $1.79, or between $1.16 and $1.20 on an as-reported basis.

Revenue in the second quarter increased 35% to $63.43 billion.

"We posted strong second quarter results, with all of our businesses performing at or above expectations," said President and CEO Larry Merlo.

Shares of CVS traded 5.1% higher at $56.85 in premarket trading. The company reported its results before U.S. markets opened Aug. 7.